Moderna, INC 8-K filings

Moderna reported Q2 2026 results with flat revenue of $145 million, a GAAP net loss of $0.8 billion, and improved operating expense outlook for the year.

Moderna, Inc. announced the appointment of Michael McDonnell, former CFO of Biogen, to its Board of Directors, effective July 8, 2026, to bolster financial leadership.

Moderna, Inc. announced amendments to its bylaws establishing federal district courts as the exclusive forum for securities-related lawsuits and reported results from its 2026 Annual Meeting of Stockholders.

Moderna reported fourth quarter and full-year 2025 financial results, including significant net losses, while outlining 2026 revenue growth targets and key pipeline advancements despite regulatory setbacks for its flu vaccine.

Moderna announced preliminary 2025 financial results exceeding prior guidance and outlined a strategic focus on seasonal vaccines and pipeline advancements for 2026.

Moderna reports strong operational execution and pipeline progress in 2025 despite a difficult U.S. environment, projecting up to 10% revenue growth in 2026.

Moderna, Inc. has entered into a $1.5 billion credit and guaranty agreement, including a $600 million initial term loan and $900 million in delayed draw term loans, to bolster liquidity and support its late-stage clinical pipeline.

Moderna announced a three-year business strategy, targeting up to 10% revenue growth in 2026, significant cost reductions, and pipeline advancements at its Analyst Day.

Moderna, Inc. shareholders approved a one-time stock option exchange program for non-Executive Committee employees at a Special Meeting held on November 12, 2025.

Moderna reported a Q3 2025 net loss of $(0.2) billion on $1.0 billion revenue, narrowing its full-year revenue guidance while improving operating expense and year-end cash projections.

Moderna, Inc. announced a 41% decrease in second-quarter 2025 revenue to $142 million, alongside a reduced net loss of $(0.8) billion, while updating its full-year revenue guidance and highlighting significant pipeline progress and cost discipline.

Moderna held its 2025 Annual Meeting of Stockholders on April 30, 2025, where directors were elected, executive compensation was approved, and the appointment of Ernst & Young LLP as the independent accounting firm was ratified.

Moderna announces Q1 2025 results with $0.1 billion in revenue, a net loss of $(1.0) billion, and reiterates its 2025 revenue guidance of $1.5 to $2.5 billion while announcing significant cost reductions.

Moderna announces Q4 revenues of $1.0 billion, a GAAP net loss of $(1.1) billion, and submits three investigational mRNA products for regulatory approval.

Moderna reports 2024 product sales of $3.0 to $3.1 billion and provides updates on its pipeline, including expected revenue and cost reductions for 2025.

Moderna announced its third quarter 2024 financial results, reporting $1.9 billion in revenue and a net income of $13 million, while also providing updates on its pipeline and executive team.

Moderna has appointed Abbas Hussain, former CEO of Vifor Pharma, to its Board of Directors, effective October 2, 2024, to enhance its global commercialization efforts.

Moderna is focusing on ten product approvals by 2027, reducing R&D spending, and advancing key vaccine candidates.

Moderna announced its second quarter 2024 financial results, including $241 million in revenue and a net loss of $1.3 billion, while also updating its 2024 financial framework and highlighting key pipeline advancements.

Moderna has appointed David M. Rubenstein to its Board of Directors, effective August 5, 2024, while Robert Langer and Stephen Berenson will retire from the board on the same date.

Moderna's stockholders approved amendments to the company's charter, including the right for shareholders holding 20% or more of outstanding shares to call a special meeting, and the exculpation of executive officers, at the 2024 Annual Meeting.

Moderna's first quarter 2024 results show a significant revenue drop to $167 million, alongside a net loss of $1.2 billion, as the company prepares for the launch of its RSV vaccine and a new Spikevax formula.

Moderna's 2023 results show a significant revenue drop and net loss, but the company anticipates regulatory approval for its RSV vaccine and continued pipeline advancements in 2024.